A three-way crossover, Phase III, pharmacokinetic study evaluating the bioavailability of RHB-105 actives versus the comparator in healthy volunteers.
Phase of Trial: Phase III
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Amoxicillin/omeprazole/rifabutin (Primary)
- Indications Helicobacter pylori infections
- Focus Pharmacokinetics
- 13 Jan 2017 New trial record
- 10 Jan 2017 According to a RedHill Biopharma media release, first patient has been dosed in this trial.